Form DEFA14A Seres Therapeutics, Inc.
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "neutral" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock, up previously from $1.25.MarketBeat
- Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire
- Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
MCRB
Earnings
- 5/7/25 - Beat
MCRB
Sec Filings
- 5/19/25 - Form 4
- 5/19/25 - Form 4
- 5/19/25 - Form 4
- MCRB's page on the SEC website